Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy. - Wikidata - wikimedia - TriplyDB

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.

http://www.wikidata.org/entity/Q37402786

about

Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: A Randomized, Double-blind, Placebo-Controlled Trial.Synergistic anti-tumor effects of liraglutide with metformin on pancreatic cancer cells.

P2860

Q51732619-16FEB178-D19B-4790-B2F9-0307F633A6E6 Q55401717-0D19D41C-D39D-4843-A44A-89C8C77C8C7D

P2860

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Clinical Update of Safety and Efficacy.

http://www.wikidata.org/entity/Q37402786

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@en

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@nl

type

label

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@en

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@nl

prefLabel

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@en

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@nl

P1433

Q37402786-AE03EA43-3B3B-4684-ADAC-D3351B516B71

P1476

Q37402786-C522028B-4D28-4BA1-BF7E-6AA87E308CC9

P2093

Q37402786-8D05E648-65B8-410B-AFB0-00A0CB21F899

P275

Q37402786-9D454C71-4EAB-48BC-B2EA-EC359886CF66

P2860

Q37402786-006B92E6-55C0-493B-9E72-B74CEC7A4112

Q37402786-010959C4-44DD-4A49-943C-D15C28E018FF

Q37402786-01DF1784-795F-4681-9C35-AF662C5E75F5

Q37402786-02DF5834-2882-44A1-845E-5FFB0C2DF530

Q37402786-0346F9D6-EE50-44D5-9C5E-0754B1F67FA7

Q37402786-0F58126B-18C3-4982-9A9D-6A174E6121F2

Q37402786-12732CAF-9196-4417-83E4-B9E056C89DDB

Q37402786-12FA8720-BD69-41D8-885A-453E13F58C9D

Q37402786-170CF7F1-F1CA-424A-A254-394B709B778D

Q37402786-1C42C0DB-D785-4A3D-955E-214DCFB01165

P304

Q37402786-D89A918A-4B34-43C1-A782-42B3629832E0

P31

Q37402786-B202116A-1A13-4ACA-8BD7-4D74142BFA34

Q37402786-C167622E-8DF1-4BFB-896E-4B86919FFC84

P356

Q37402786-254D5A3E-F520-41ED-A947-22F5D38F712F

P433

Q37402786-1F63CFFC-2199-4F3D-A959-B93C457DD562

P478

Q37402786-168D2D0E-0C40-412E-9564-178B06F55EBF

P5008

Q37402786-9AB7A686-C059-40C3-B556-90886D30B020

P577

Q37402786-FA402A8A-F53A-43C3-B9CE-BC97681DFDBE

P698

Q37402786-F619F948-A372-475F-8CB8-4C48737061B4

P921

Q37402786-3225F8B1-8D6D-42B0-A892-64548B2DCFA3

Q37402786-7EFC06C4-38BE-4E33-9887-73932EF581C7

Q37402786-C034ABD1-9C4B-43D4-AA84-935BD466E04F

Q37402786-C13231BE-7900-402B-A4AD-B96315247C3F

P932

Q37402786-5C85047A-8A23-4885-81E0-B2A5654087A5

P356

1573399812666151223093841

P1433

Current Diabetes Reviews

P1476

Glucagon-Like Peptide-1 Recept ...... Update of Safety and Efficacy.

@en

P2093

Scott R Drab

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects.

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis.

P304

403-413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2174/1573399812666151223093841

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2015-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26694823

http://www.w3.org/2001/XMLSchema#string

P921

cell surface receptor

type-2 diabetes

membrane proteins

maturity-onset diabetes of the young

P932

5101635

http://www.w3.org/2001/XMLSchema#string